stephh
2021-08-19
Like and comment. Thanks.
Pfizer Ousts Moderna as Day Traders’ Favorite Vaccine Maker
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":831483443,"tweetId":"831483443","gmtCreate":1629340732482,"gmtModify":1631893749215,"author":{"id":3575058137963235,"idStr":"3575058137963235","authorId":3575058137963235,"authorIdStr":"3575058137963235","name":"stephh","avatar":"https://static.tigerbbs.com/7e248aeda9d24c835ab13541550241cf","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment. Thanks. </p></body></html>","htmlText":"<html><head></head><body><p>Like and comment. Thanks. </p></body></html>","text":"Like and comment. Thanks.","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/831483443","repostId":1113170668,"repostType":4,"repost":{"id":"1113170668","pubTimestamp":1629340449,"share":"https://www.laohu8.com/m/news/1113170668?lang=&edition=full","pubTime":"2021-08-19 10:34","market":"us","language":"en","title":"Pfizer Ousts Moderna as Day Traders’ Favorite Vaccine Maker","url":"https://stock-news.laohu8.com/highlight/detail?id=1113170668","media":"Bloomberg","summary":"Move over Moderna Inc., Pfizer Inc. is the new day traders’ favorite Covid-19 vaccine stock.\nPfizer ","content":"<p>Move over Moderna Inc., Pfizer Inc. is the new day traders’ favorite Covid-19 vaccine stock.</p>\n<p>Pfizer climbed about 9% in the the four trading days through Tuesday, with retail traders snapping up about $63 million of the shares on Tuesday alone, according to data from Vanda Research. The day-trading crowd sold off more positions than they bought in Moderna and BioNTech.</p>\n<p>It marks a sharp change in fortunes. Both Moderna and BioNTech have amassed triple digit gains this year, a rally the nearly $280 billion-valued Pfizer missed out on with a scant 34% gain, despite being the first -- along with BioNTech -- to win authorization for a Covid shot in the U.S. The U.S. announced today that it would start offering booster shots to the already vaccinated in September.</p>\n<p>As Pfizer rallies, BioNTech has tumbled more than 18% from a record high reached on Aug. 9, while Moderna is down roughly 18% from its zenith. All three stocks slumped today, with Pfizer reversing early gains to close down 2.2%.</p>\n<p><img src=\"https://static.tigerbbs.com/a3d600adb9aa0c5dff206181e7ec2999\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>Pfizer’s stock now trades at about an 8% premium to the average analyst price target, compared to more than 30% for Moderna and 18% for BioNTech.</p>\n<p>The recent closing of the gap may not spell the end of the rally. Wall Street is already adjusting its models with Pfizer getting a new Wall Street high price target of $61 from Cantor Fitzgerald analyst Louise Chen on Tuesday.</p>\n<p>The drugmaker’s “pipeline advancements and product sales continue to exceed our expectations,” she wrote in a note to clients.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Ousts Moderna as Day Traders’ Favorite Vaccine Maker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Ousts Moderna as Day Traders’ Favorite Vaccine Maker\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 10:34 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-08-18/pfizer-ousts-moderna-as-day-trader-s-favorite-vaccine-maker?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over Moderna Inc., Pfizer Inc. is the new day traders’ favorite Covid-19 vaccine stock.\nPfizer climbed about 9% in the the four trading days through Tuesday, with retail traders snapping up about...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-18/pfizer-ousts-moderna-as-day-trader-s-favorite-vaccine-maker?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-18/pfizer-ousts-moderna-as-day-trader-s-favorite-vaccine-maker?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113170668","content_text":"Move over Moderna Inc., Pfizer Inc. is the new day traders’ favorite Covid-19 vaccine stock.\nPfizer climbed about 9% in the the four trading days through Tuesday, with retail traders snapping up about $63 million of the shares on Tuesday alone, according to data from Vanda Research. The day-trading crowd sold off more positions than they bought in Moderna and BioNTech.\nIt marks a sharp change in fortunes. Both Moderna and BioNTech have amassed triple digit gains this year, a rally the nearly $280 billion-valued Pfizer missed out on with a scant 34% gain, despite being the first -- along with BioNTech -- to win authorization for a Covid shot in the U.S. The U.S. announced today that it would start offering booster shots to the already vaccinated in September.\nAs Pfizer rallies, BioNTech has tumbled more than 18% from a record high reached on Aug. 9, while Moderna is down roughly 18% from its zenith. All three stocks slumped today, with Pfizer reversing early gains to close down 2.2%.\n\nPfizer’s stock now trades at about an 8% premium to the average analyst price target, compared to more than 30% for Moderna and 18% for BioNTech.\nThe recent closing of the gap may not spell the end of the rally. Wall Street is already adjusting its models with Pfizer getting a new Wall Street high price target of $61 from Cantor Fitzgerald analyst Louise Chen on Tuesday.\nThe drugmaker’s “pipeline advancements and product sales continue to exceed our expectations,” she wrote in a note to clients.","news_type":1},"isVote":1,"tweetType":1,"viewCount":59,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":22,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/831483443"}
精彩评论